«Центр ветеринарной помощи» (Главный ветеринарный врач)
Россия
ООО «АГ «Аспект» (Научный консультант)
ООО «НВП «Астрафарм» (Научный консультант)
Россия
ООО «АГ «Аспект» (Ветеринарный врач)
ООО «НВП «Астрафарм» (Ведущий ветеринарный врач)
Россия
ООО «НВП «Астрафарм» (Главный специалист по науке)
Россия
ГРНТИ 68.41 Ветеринария
Применение лекарственного препарата Курс Успокоин таблетки в минимальной начальной суточной дозе 7 мг/кг первые три дня, с дальнейшим ее увеличением до 14 мг/кг показало положительный эффект при коррекции поведения кошек старше 10 лет с прогрессирующими признаками когнитивных нарушений. В ходе курсовой терапии у животных зарегистрировано статистически и клинически значимое снижение идиопатической вокализации, восстановление режима сна и бодрствования, устранение нечистоплотного поведения, дезориентации в пространстве, повышение активности, улучшение социального поведения. В ходе применения лекарственного препарата Курс Успокоин таблетки и после его отмены нежелательных реакций у животных не зарегистрировано.
сукцинат тразодона, Курс Успокоин таблетки, кошки, возрастные когнитивные нарушения, стареющие кошки, серотониновая система, нейромедиатор
1. O’Neill D.G., Church D.B., McGreevy P.D., Thomson P.C., Brodbelt D.C., Longevity and mortality of cats attending primary care veterinary practices in England, J. Feline Med. Surg., 2015, No. 17, pp. 125-133. doi:https://doi.org/10.1177/1098612X14536176.
2. Egenvall A., Bonnett B.N., Häggström J., Ström Holst B., Möller L., Nødtvedt A., Morbidity of insured Swedish cats during 1999–2006 by age, breed, sex, and diagnosis, J. Feline Med. Surg., 2010, No. 12, pp. 948-959. doi:https://doi.org/10.1016/j.jfms.2010.08.008.
3. Laflamme D., Gunn-Moore D., Nutrition of aging cats, Vet. Clin. North Am. Small Anim. Pract., 2014, No. 44, pp. 761-774. doi:https://doi.org/10.1016/j.cvsm.2014.03.001.
4. Gunn-Moore D.A., Cognitive Dysfunction in the Cat. In: Little S.E., August J.R., editors. August’s Consultation in Feline Internal Medicine. Vol. 7. Vol. 42. Elsevier Saunders; Philadelphia, PA, USA, 2016. 977-985 p.
5. Laflamme D.P., Abood S.K., Fascetti A.J., Fleeman L.M., Freeman L.M., Michel K.E., Bauer C., Kemp B.L., Doren J.R., Willoughby K.N., Pet feeding practices of dog and cat owners in the United States and Australia, J. Am. Vet. Med Assoc., 2008, No. 232, pp. 687-694. doi:https://doi.org/10.2460/javma.232.5.687.
6. Landsberg G., Behavior problems of older cats, in Schaumburg I (ed): Proceedings of the 135th Annual Meeting of the American Veterinary Medical Association, San Diego, CA, 1998, 317-320 p.
7. The effects of aging on behavior in senior pets. Available at https://veteriankey.com/the-effects-of-aging-on-behavior-in-senior-pets/#bib1
8. De Boer S.F., Olivier B., Veening J., Koolhaas J.M., The neurobiology of offensive aggression: revealing a modular view. Physiology & Behavior, 2015, No. 146, pp. 111-127.
9. Fredrika R., The role of serotonin in animal personality. Linköping University, Department of Physics, Chemistry and Biology, 2017, 13 p.
10. Bacqué-Cazenave J., Bharatiya R., Barrière G., Delbecque J-P., Bouguiyoud N., Di Giovanni G., Cattaert D., De Deurwaerdère Ph., Serotonin in Animal Cognition and Behavior, Int J Mol Sci., 2020 Mar, No. 21(5), pp. 1649.
11. Amat M., de la Torre J.L.R., Fatjó J., Mariotti V.M., Van Wijk S., Ruiz-de-la-Torre J.L., Manteca X.. Potential risk factors associated with feline behaviour problems, Applied Animal Behaviour Science, 2009, No. 121(2), pp. 134-139.
12. Vachon L., Roberge A.G., Involvement of serotonin and catecholamine metabolism in cats trained to perform a delayed response task. Neuroscience, 1981, No. 6(2), pp. 189-194. doihttps://doi.org/10.1016/0306-4522(81)90054-3.
13. Patricia A.P., Benjamin L., Kelly D.C., Melissa J.B., Effects of a selective serotonin reuptake inhibitor on urine spraying behavior in cats, JAVMA, 2001 December 1, Vol. 219, No. 11, pp.1557-1561.
14. Rodriguez J.J., Noristani H.N., Verkhratsky A., The serotonergic system in ageing and Alzheimer’s disease. Prog. Neurobiol., 2012, No. 99, pp. 15-41.
15. Meltzer H., Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behavioural brain research., 2008 Dec 16;195(1):98-102.
16. Hall H., Lundkvist C., Halldin C., Farde L., Pike V.W., McCarron J.A., Autoradiographic localization of 5-HT1A receptors in the postmortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res., 1997, No. 745, pp. 96-108.
17. Tauscher J., Verhoeff N.P., Christensen B.K., Hussey D., Meyer J.H., Kecojevic A., Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C] WAY-100635 and PET, Neuropsychopharmacology, 2001, No. 24, pp. 522-530.
18. Li Z., Ichikawa J., Dai J., Meltzer H.Y., Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain, Eur. J. Pharmacol., 2004. No. 493, pp. 75-83.
19. Bantick R.A., De Vries M.H., Grasby P.M., The effect of a 5-HT1A receptor agonist on striatal dopamine release, Synapse, 2005, No. 57, pp. 67-75.
20. Blazer D., Williams C.D., Epidemiology of dysphoria and depression in the elderly population, Am J Psychiatry, 1980, No. 137, pp. 439-444.
21. Mann J.J., Arango V., Underwood M.D., Serotonin and suicidal be-havior, Ann NY Acad Sci, 1990, No. 600, pp. 476-485.
22. Meltzer C.C., Smith G., De Kosky S.T., Pollock В.G., Serotonin in Aging, Late Life Depression and Alzheimer’s Disease: The Emerging Role of Functional Imaging, Neuropsychopharmacology, 1998, Vol. 18, pp. 407-430.
23. Kakiuchi T., Tsukada H., Fukumoto D., Nishiyama S., Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [11C](1)McN5652 and [11C](-)McN5652 in con-scious monkeys, Synapse, 2001, No. 40, pp. 170-179.
24. Arora R.C., Gulati A., Crayton J.W., Aging and [3 H]paroxetine binding in rat brain: effect of imipramine and tetrahydroacridine, Life Sci, 1993, No. 52, pp. 1767-1775.
25. Rood B.D., Calizo L.H., Piel D. Serotonin Neurons in Mice: Immature Hy-perexcitability Transitions to Adult State during First Three Postnatal Weeks Suggesting Sensitive Period for Environmental Perturbation, Journal of Neuro-science, 2 April 2014, No. 34 (14), pp. 4809-4821; DOI: https://doi.org/10.1523/JNEUROSCI.1498-13.2014.
26. Cuomo A., Bianchetti A., Cagnin A., De Berardis D., Di Fazio I., Antonelli R., Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use, Journal of Gerontology and Geriatrics, 2021 June, Vol. 69, Is. 2, pp. 1-10.
27. Simpson D.M., Foster D., Improvement in organically disturbed behavior with trazodone treatment, J Clin Psychiatry, 1986, No. 47, pp. 191-193.
28. Tingle D., Trazodone in dementia (letter). J Clin Psychiatry, 1986, No. 47, pp. 482.
29. Greenwald B.S., Marin D.B., Silverman S.M., Serotoninergic treatment of screaming and banging in dementia (letter), Lancet, 1986, No. 2 (8521-8522), pp. 1464-1465.
30. Pinner E., Rich C.L., Effects of trazodone on aggressive behavior in seven patients with organic mental disorders, Am J Psychiatry, 1988, No. 145, pp. 1295-1296.
31. Houlihan D.J., Mulsant B.H., Sweet R.A., et al., A naturalistic study of trazodone in the treatment of behavioral complications of dementia, Am J Geriatr Psychiatry, 1994, No. 2, pp. 78-85.
32. Lebert F., Pasquier F., Petit H., Behavioral effects of trazodone in Alzheimer's disease, J Clin Psychiatry, 1994, No. 55, pp. 536-538.
33. Lebert F., et al., Frontotemporal dementia: a randomised, controlled trial with trazodone, Dement Geriatr Cogn Disord, 2004, No. 17(4), pp. 355-349.
34. Managing Cognitive Dysfunction and Behavioral Anxiety. Available at: https://www.aaha.org/aaha-guidelines/2023-aaha-senior-careguidelines-for-dogs-and-cats/managing-cognitive-dysfunction-andbehavioral-anxiety/
35. Managing Cognitive Dysfunction and Behavioral Anxiety. Available at: https://www.aaha.org/aaha-guidelines/2023-aaha-senior-care-guidelines-for-dogs-and-cats/managing-cognitive-dysfunction-and-behavioral-anxiety/
36. Daniele S., Da Pozzo E., Zappelli E., Claudia C., Trazodone treatment protects neuronal-like cells from inflammatory insult by inhibiting NFkB, p38 and JNK. Department of Pharmacy, University of Pisa, Italy., 2015, pp. 34.
37. Orlando J.M., Case B.C., Thomson A.E., Griffith E., Sherman B.L., Use of oral trazodone for sedation in cats: A pilot study, J. Feline Med. Surg., 2016, No. 18, pp. 476-482.
38. Stevens B.J., Frantz E.M., Orlando J.M., Griffith E., Harden L.B. et al., Efficacy of a single dose of trazodone hydrochloride given to cats prior to veterinary visits to reduce signs of transport- and examination-related anxiety, J. Am. Vet. Med. Assoc., 2016, No. 249, pp. 202-207.
39. Gunn-Moore D.A. Cognitive dysfunction in cats: clinical assessment and management, Top Companion Anim Med., 2011 Feb, No. 26(1), pp. 17-24. doi:https://doi.org/10.1053/j.tcam.2011.01.005.
40. Chea B., Giorgi M., Trazodone: A Review of Its Pharmacological Properties and Its Off-Label Use in Dogs and Cats, American Journal of Animal and Veterinary Sciences, 2017, No. 12 (4), pp. 188-194.
41. Shin J.J., Saadabadi A., Trazodone, Available at: https://www.ncbi.nlm.nih.gov/books/NBK470560/
42. Beasley C.M.Jr, Dornseif B.E., Pultz J.A., et al., Fluoxetine versus trazodone: efficacy and activating-sedating effects, J Clin Psychiatry, 1991, No. 52(7), pp. 294-299.
43. Cunningham L.A., Borison R.L., Carman J.S., et al. A comparison of venlafaxine, trazodone, and placebo in major depression, J Clin Psychopharmacol., 1994, No. 14(2), pp. 99-106. doi:https://doi.org/10.1097/00004714-199404000-00003.
44. Kasper S., Olivieri L., Di Loreto G., Dionisio P., A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin., 2005, No. 21(8), pp. 1139-1146. doi:https://doi.org/10.1185/030079905X53243.
45. Moon C.A., Laws D., Stott P.C., Hayes G., Efficacy and tolerability of controlled-release trazodone in depression: a large multicentre study in general practice, Curr Med Res Opin., 1990, No. 12(3), pp. 160-168. doi:https://doi.org/10.1185/03007999009111497.
46. Munizza C., Olivieri L., Di Loreto G., Dionisio P., A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder, Curr Med Res Opin., 2006, No. 22(9), pp. 1703-1713. doi:https://doi.org/10.1185/030079906X121039.
47. Sheehan D.V., Croft H.A., Gossen E.R., et al., Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry. 2009, No. 6(5). pp. 20-33.
48. Sheehan D.V., Rozova A., Gossen E.R., Gibertini M., The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder, Psychopharmacol Bull, 2009, No. 42(4), pp. 5-22.
49. van Moffaert M., de Wilde J., Vereecken A., et al., Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression, Int Clin Psychopharmacol., 1995, No. 10(1), pp. 3-9. doi:https://doi.org/10.1097/00004850-199503000-00001.
50. Weisler R.H., Johnston J.A., Lineberry C.G., et al., Comparison of bupropion and trazodone for the treatment of major depression, J Clin Psychopharmacol., 1994, No. 14(3), pp. 170-179. doi:https://doi.org/10.1097/00004714-199406000-00004.
51. Blacker R., Shanks N.J., Chapman N., Davey A., The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline, Psychopharmacology. 1988, No. 95(Suppl), S18-S24.
52. Botros W.A., Ankier S.I., Priest R.G., et al., Clinical assessment and performance tasks in depression: a comparison of amitriptyline and trazodone. Br J Psychiatry, 1989, No. 155, pp. 479-482. doi:https://doi.org/10.1192/bjp.155.4.479.
53. Davey A., A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice. Psychopharmacology, 1988, No. 95(Suppl), S25-S30.
54. Debus J.R., Rush A.J., Himmel C., et al., Fluoxetine versus trazodone in the treatment of outpatients with major depression, J Clin Psychiatry, 1988, No. 49(11), pp. 422-426.
